Inhibition of CDCP1 by 8-isopentenylnaringenin synergizes with EGFR inhibitors in lung cancer treatment.
Sign Up to like & getrecommendations! Published in 2023 at "Molecular oncology"
DOI: 10.1002/1878-0261.13429
Abstract: CUB domain-containing protein 1 (CDCP1) contributes to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) resistance by regulating EGFR signaling pathways and is a potential target in lung cancer treatment. This study aims to… read more here.
Keywords: lung cancer; cdcp1; treatment; cancer ... See more keywords
Targeting YAP‐p62 signaling axis suppresses the EGFR‐TKI‐resistant lung adenocarcinoma
Sign Up to like & getrecommendations! Published in 2021 at "Cancer Medicine"
DOI: 10.1002/cam4.3734
Abstract: Despite the progress of advanced target therapeutic agents and immune checkpoint inhibitors, EGFR‐TKI resistance is still one of the biggest obstacles in treating lung cancer. Clinical studies with autophagy inhibitors are actively underway to overcome… read more here.
Keywords: egfr tki; tki; targeting yap; p62 signaling ... See more keywords
Discontinuation of tyrosine kinase inhibitor in chronic myeloid leukemia: a retrospective cohort in east occitania
Sign Up to like & getrecommendations! Published in 2022 at "Annals of Hematology"
DOI: 10.1007/s00277-022-04779-x
Abstract: Tyrosine kinase inhibitor (TKI) discontinuation in chronic phase chronic myeloid leukemia (CML) patients has been examined in a real-life setting in the east occitania region of France. We have collected sex, age, prognostic scores, pre-TKI… read more here.
Keywords: tyrosine kinase; kinase inhibitor; discontinuation; tki ... See more keywords
Osimertinib in poor performance status patients with T790M-positive advanced non-small-cell lung cancer after progression of first- and second-generation EGFR-TKI treatments (NEJ032B)
Sign Up to like & getrecommendations! Published in 2021 at "International Journal of Clinical Oncology"
DOI: 10.1007/s10147-021-02043-2
Abstract: Osimertinib is effective in patients with T790M mutation-positive advanced non-small-cell lung cancer (NSCLC) resistant to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). However, its effectiveness and safety in patients with poor performance status… read more here.
Keywords: egfr; tki; positive advanced; progression ... See more keywords
Fertility considerations in targeted biologic therapy with tyrosine kinase inhibitors: a review
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Assisted Reproduction and Genetics"
DOI: 10.1007/s10815-021-02181-6
Abstract: To review the impact of tyrosine kinase inhibitors (TKIs) on fertility in men and women, embryo development, and early pregnancy, and discuss considerations for fertility preservation in patients taking TKIs. A comprehensive literature search using… read more here.
Keywords: kinase inhibitors; pregnancy; fertility; tyrosine kinase ... See more keywords
Bevacizumab Reduces S100A9‐Positive MDSCs Linked to Intracranial Control in Patients with EGFR‐Mutant Lung Adenocarcinoma
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Thoracic Oncology"
DOI: 10.1016/j.jtho.2018.03.032
Abstract: Introduction: In vitro models have demonstrated immune‐modulating effects of bevacizumab (BEV). Combinations of an EGFR tyrosine kinase inhibitor (TKI) with BEV improve progression‐free survival (PFS) in patients with EGFR‐mutated lung adenocarcinoma. How BEV confers this… read more here.
Keywords: lung adenocarcinoma; mdscs; bev; tki group ... See more keywords
Comparison of up-front radiotherapy and TKI with TKI alone for NSCLC with brain metastases and EGFR mutation: A meta-analysis.
Sign Up to like & getrecommendations! Published in 2018 at "Lung cancer"
DOI: 10.1016/j.lungcan.2018.05.014
Abstract: OBJECTIVE About 50-70% non-small cell lung cancer (NSCLC) patients with EGFR mutation go through brain metastases (BM). Radiotherapy is the standard treatment before the tyrosine kinase inhibitor (TKI) era. However, the TKI has more than… read more here.
Keywords: brain metastases; egfr mutation; tki alone; front radiotherapy ... See more keywords
[Pulmonary manifestations induced by osimertinib].
Sign Up to like & getrecommendations! Published in 2021 at "Revue des maladies respiratoires"
DOI: 10.1016/j.rmr.2021.12.002
Abstract: INTRODUCTION The third-generation tyrosine kinase inhibitor (TKI) osimertinib is recommended as a first-line treatment in advanced non-small cell lung cancer harboring an activating mutation of Epidermal Growth Factor Receptor (EGFR). Adverse pulmonary events related to… read more here.
Keywords: induced osimertinib; lung; pulmonary manifestations; manifestations induced ... See more keywords
Targeted therapies: Remembrance of things past — discontinuation of second-generation TKI therapy for CML
Sign Up to like & getrecommendations! Published in 2017 at "Nature Reviews Clinical Oncology"
DOI: 10.1038/nrclinonc.2017.11
Abstract: Data from the recent Stop 2G-TKI study confirm that around 60% of patients with chronic myeloid leukaemia who discontinue second-generation BCR–ABL1 tyrosine-kinase inhibitor (TKI) therapy after a sustained deep molecular response remain in remission for… read more here.
Keywords: tki therapy; second generation; discontinuation; tki ... See more keywords
First-line anti-VEGF plus EGFR-TKI in EGFR-mutant NSCLC: adding the ARTEMIS trial to the puzzle of current evidence
Sign Up to like & getrecommendations! Published in 2021 at "Signal Transduction and Targeted Therapy"
DOI: 10.1038/s41392-021-00813-y
Abstract: In the ARTEMIS-CTONG1509 multicenter phase 3 study recently published in Cancer Cell, Zhou et al. investigate the combination of the EGFR tyrosine kinase inhibitor (TKI) erlotinib and antiangiogenic bevacizumab in treatment-naive Chinese patients with advanced… read more here.
Keywords: egfr mutant; line anti; vegf plus; anti vegf ... See more keywords
Targeting nicotinamide N-methyltransferase overcomes resistance to EGFR-TKI in non-small cell lung cancer cells
Sign Up to like & getrecommendations! Published in 2022 at "Cell Death Discovery"
DOI: 10.1038/s41420-022-00966-x
Abstract: Activating mutations of epidermal growth factor receptor (EGFR) contributes to the progression of non-small cell lung cancer (NSCLC). EGFR tyrosine kinase inhibitor (TKI)-targeted therapy has become the standard treatment for NSCLC patients with EGFR-mutations. However,… read more here.
Keywords: tki; cell; resistance egfr; egfr tki ... See more keywords